These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29808092)

  • 21. Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study.
    Kim SS; Kim IJ; Lee KJ; Park JH; Kim YI; Lee YS; Chung SC; Lee SJ
    J Diabetes; 2017 Apr; 9(4):412-422. PubMed ID: 27229178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy.
    Tai H; Wang MY; Zhao YP; Li LB; Dong QY; Liu XG; Kuang JS
    Medicine (Baltimore); 2016 Aug; 95(33):e4541. PubMed ID: 27537577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study).
    Nomoto H; Takahashi A; Nakamura A; Kurihara H; Takeuchi J; Nagai S; Taneda S; Miya A; Kameda H; Cho KY; Miyoshi H; Atsumi T
    BMJ Open Diabetes Res Care; 2022 Nov; 10(6):. PubMed ID: 36379585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial.
    Yang W; Dong X; Li Q; Cheng Z; Yuan G; Liu M; Xiao J; Gu S; Niemoeller E; Chen L; Ping L; Souhami E;
    Diabetes Obes Metab; 2022 Aug; 24(8):1522-1533. PubMed ID: 35441412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chinese herbal medicine for impaired glucose tolerance: a randomized placebo controlled trial.
    Grant SJ; Chang DH; Liu J; Wong V; Kiat H; Bensoussan A
    BMC Complement Altern Med; 2013 May; 13():104. PubMed ID: 23672597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial.
    Philis-Tsimikas A; Asong M; Franek E; Jia T; Rosenstock J; Stachlewska K; Watada H; Kellerer M
    Lancet Diabetes Endocrinol; 2023 Jun; 11(6):414-425. PubMed ID: 37148899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study.
    Frias J; Chien J; Zhang Q; Chigutsa E; Landschulz W; Syring K; Wullenweber P; Haupt A; Kazda C
    Lancet Diabetes Endocrinol; 2023 Mar; 11(3):158-168. PubMed ID: 36758572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The iHealth-T2D study, prevention of type 2 diabetes amongst South Asians with central obesity and prediabetes: study protocol for a randomised controlled trial.
    Kasturiratne A; Khawaja KI; Ahmad S; Siddiqui S; Shahzad K; Athauda LK; Jayawardena R; Mahmood S; Muilwijk M; Batool T; Burney S; Glover M; Palaniswamy S; Bamunuarachchi V; Panda M; Madawanarachchi S; Rai B; Sattar I; Silva W; Waghdhare S; Jarvelin MR; Rannan-Eliya RP; Gage HM; van Valkengoed IGM; Valabhji J; Frost GS; Loh M; Wickremasinghe AR; Kooner JS; Katulanda P; Jha S; Chambers JC
    Trials; 2021 Dec; 22(1):928. PubMed ID: 34922608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative efficacy and safety of two insulin aspart formulations (Rapilin and NovoRapid) when combined with metformin, for patients with diabetes mellitus: a multicenter, randomized, open-label, controlled clinical trial.
    Yao J; Guo X; Sun L; Han P; Lv X; Zhang X; Mo Z; Yang W; Zhang L; Wang Z; Zhu L; Li Q; Yang T; Wang W; Xue Y; Shi Y; Lu J; Peng Y; Zhang F; Yan D; Wang D; Yu X
    Curr Med Res Opin; 2022 Nov; 38(11):1797-1806. PubMed ID: 35833285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of traditional chinese medicine for diabetes: a double-blind, randomised, controlled trial.
    Ji L; Tong X; Wang H; Tian H; Zhou H; Zhang L; Li Q; Wang Y; Li H; Liu M; Yang H; Gao Y; Li Y; Li Q; Guo X; Yang G; Zhang Z; Zhou Z; Ning G; Chen Y; Paul S;
    PLoS One; 2013; 8(2):e56703. PubMed ID: 23460810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Short-term intensive combined therapy with metformin, sagliptin and dapagliflozin for newly diagnosed type 2 diabetes: efficacy, weight control and safety].
    Xu Y; Wu P; Wen W; Chen H
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Nov; 39(11):1305-1311. PubMed ID: 31852646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
    Rosenstock J; Rood J; Cobitz A; Biswas N; Chou H; Garber A
    Diabetes Obes Metab; 2006 Nov; 8(6):650-60. PubMed ID: 17026489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Basal Insulin-Based Treatment Versus Twice-Daily Premixed Insulin After Short-Term Intensive Insulin Therapy in Patients with Type 2 Diabetes Mellitus in China: Study Protocol for a Randomized Controlled Trial (BEYOND V).
    Liu J; Jiang X; Xu B; Wang G; Cui N; Zhang X; Liu J; Mu Y; Guo L
    Adv Ther; 2020 Apr; 37(4):1675-1687. PubMed ID: 32130661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].
    ; ;
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Feb; 47(2):101-119. PubMed ID: 38309959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial.
    Yang W; Min K; Zhou Z; Li L; Xu X; Zhu D; Venkateshwar Rao A; Murthy LS; Zhang N; Li I; Niemoeller E; Shang S
    Diabetes Obes Metab; 2018 Feb; 20(2):335-343. PubMed ID: 28742225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of a combination of recombinant human growth hormone with metformin on glucose metabolism and body composition in patients with metabolic syndrome.
    Herrmann BL; Berg C; Vogel E; Nowak T; Renzing-Koehler K; Mann K; Saller B
    Horm Metab Res; 2004 Jan; 36(1):54-61. PubMed ID: 14983408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.
    Rizos CV; Milionis HJ; Kostapanos MS; Florentin M; Kostara CE; Elisaf MS; Liberopoulos EN
    Clin Ther; 2010 Mar; 32(3):492-505. PubMed ID: 20399986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.